TMS therapy and Spravato® in Wesley Chapel and Tampa
Florida TMS Clinic
Call

Rapid-acting depression treatment

Spravato® (esketamine) in Wesley Chapel and Tampa

Medically reviewed by Dr. Khaled Bowarshi, M.D., board-certified psychiatristUpdated November 1, 2026

FDA-approved, clinic-administered therapy for severe or treatment-resistant depression and for major depression with suicidal thoughts or behavior, available at Florida TMS Clinic.

Quick facts

What it is
Spravato® (esketamine) nasal spray, self-administered under supervision.
FDA-approved for
Treatment-resistant depression, and major depression with suicidal thoughts or behavior.
Trial results
Improvement measured as early as 4 hours, with significant benefit at 24 hours.
Visit length
About 2 hours including observation and recovery.
Safety
REMS-certified care with blood pressure monitoring.
Locations
Wesley Chapel and Tampa, Florida.

What is Spravato® (esketamine)?

Esketamine is the S-enantiomer of ketamine, delivered as a nasal spray under physician supervision. Unlike SSRIs or SNRIs, it targets the brain's glutamate system (the NMDA receptor) to enhance neuroplasticity. Many patients experience meaningful symptom relief in hours to days rather than weeks.

Proven, rapid results

In a Phase 3 randomized trial of adults with major depressive disorder and active suicidal ideation, esketamine plus standard care produced significantly greater improvement on the MADRS depression scale at 4 to 24 hours compared with placebo plus standard care, with benefits maintained during the 4-week acute phase.

  • Clinically meaningful improvement by 4 hours
  • Statistically significant benefit at 24 hours
  • Common effects are transient (for example dizziness, brief dissociation, mild increase in blood pressure)

Esketamine is FDA-approved for treatment-resistant depression and for major depression with suicidal thoughts or behavior. Treatment occurs only in certified clinics under the REMS program.

Who is it for?

  • Treatment-resistant depression (after at least two adequate antidepressant trials)
  • Major depression with suicidal thoughts or behavior needing rapid symptom reduction
  • Adults seeking evidence-based, rapid-acting depression treatment in Florida

What to expect at Florida TMS Clinic

  • Private, comfortable treatment room with continuous monitoring
  • Self-administered Spravato® nasal spray under clinician supervision
  • Each visit takes about 2 hours including observation and recovery
  • Typical schedule: twice weekly during the acute phase, then taper
  • No driving until the next day after each session
  • Used alongside an oral antidepressant for stability and durability

Safety and monitoring

We follow all REMS safety requirements. Blood pressure and comfort are monitored throughout. Most temporary effects resolve within 1 to 2 hours.

If you are in immediate crisis, call 988 (Suicide & Crisis Lifeline) or 911.

Esketamine in Wesley Chapel and Tampa

Florida TMS Clinic, Tampa: serving Tampa, South Tampa, Downtown, and Westshore. Same-week evaluations often available.

Florida TMS Clinic, Wesley Chapel: serving Wesley Chapel, New Tampa, Lutz, Land O' Lakes, and North Tampa communities.

Take the first step toward relief

If you are searching for esketamine in Tampa or Spravato® treatment in Wesley Chapel, our team can help you find rapid relief with a personalized plan that may also include TMS and psychotherapy when appropriate.

References: Ionescu DF et al., Int J Neuropsychopharmacology, 2021; Spravato® Prescribing Information (Janssen).

Next steps

A psychiatric evaluation confirms whether Spravato® is right for you. Call (813) 867-2378 to schedule in Wesley Chapel or Tampa.

Frequently asked questions

Sources and further reading

  1. SPRAVATO (esketamine) prescribing information. Revised April 2025. U.S. Food and Drug Administration
  2. SPRAVATO (esketamine hydrochloride) nasal spray, current label. DailyMed / U.S. National Library of Medicine
  3. Daly EJ, et al. Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression. JAMA Psychiatry. 2019;76:893–903. JAMA Psychiatry
  4. Reif A, et al. Esketamine nasal spray versus quetiapine for treatment-resistant depression. N Engl J Med. 2023;389:1298–1309. New England Journal of Medicine
  5. Ionescu DF, et al. Esketamine nasal spray for rapid reduction of depressive symptoms in major depressive disorder with active suicidal ideation (ASPIRE II). 2021. International Journal of Neuropsychopharmacology

Medical information on this page is educational and not a substitute for professional advice. Individual results vary.